Table 1:
Patient characteristics and demographics
| Characteristic | Cabozantinib | Weekly Paclitaxel | Total number | |||
|---|---|---|---|---|---|---|
| n | % | n | % | |||
| Age (years) | 30-39 | 1 | 1.8 | 1 | 1.9 | 2 |
| 40-49 | 5 | 8.8 | 4 | 7.4 | 9 | |
| 50-59 | 21 | 36.8 | 19 | 35.2 | 40 | |
| 60-69 | 20 | 35.1 | 24 | 44.4 | 44 | |
| 70-79 | 9 | 15.8 | 6 | 11.1 | 15 | |
| ≥ | 1 | 1.8 | 0 | 0 | 1 | |
| Race | Asian | 1 | 1.8 | 3 | 5.6 | 4 |
| Black | 4 | 7 | 2 | 3.7 | 6 | |
| American Indian | 0 | 0 | 1 | 94.4 | 1 | |
| Pacific Islander | 1 | 1.8 | 0 | 1.9 | 1 | |
| White | 50 | 87.7 | 48 | 88.9 | 98 | |
| Unknown | 1 | 1.8 | 0 | 0 | 1 | |
| Performance Status | 0 | 40 | 70.2 | 40 | 74.1 | 80 |
| 1 | 17 | 29.8 | 14 | 25.9 | 31 | |
| Cell Type/Grade | Endometrioid Grade 2 or 3 | 1 | 1.8 | 2 | 3.8 | 3 |
| Serous | 46 | 80.7 | 46 | 85.2 | 92 | |
| Clear cell | 4 | 7.0 | 1 | 1.9 | 5 | |
| Mixed Epithelial | 3 | 5.3 | 1 | 1.9 | 4 | |
| Adenocarcinoma NOS | 2 | 3.5 | 2 | 3.7 | 4 | |
| Mucinous | 1 | 1.8 | 1 | 1.9 | 2 | |
| Transitional cell | 0 | 0 | 1 | 1.9 | 1 | |
| Number of Prior regimens | 1 | 22 | 38.6 | 23 | 42.6 | 45 |
| 2 | 26 | 45.6 | 22 | 40.7 | 48 | |
| 3 | 9 | 15.8 | 9 | 16.7 | 18 | |
| Prior Radiation | No | 55 | 96.5 | 52 | 96.3 | 107 |
| Yes | 2 | 3.5 | 2 | 3.7 | 4 | |
| Prior Immunotherapy | No | 57 | 100 | 53 | 98.1 | 110 |
| Yes | 0 | 0 | 1 | 1.9 | 1 | |
| Prior Surgery | No | 1 | 1.8 | 0 | 0 | 1 |
| Yes | 56 | 98.2 | 54 | 100.0 | 110 | |
| Prior Bevacizumab | No | 46 | 80.7 | 41 | 75.9 | 87 |
| Yes | 11 | 19.3 | 13 | 24.1 | 24 | |
| Measurable Disease | No | 9 | 15.8 | 8 | 14.8 | 17 |
| Yes | 48 | 84.2 | 46 | 85.2 | 94 | |
| Platinum sensitivity | Platinum resistant <6 mo PFI | 28 | 49.1 | 27 | 50.0 | 55 |
| Platinum sensitive 6-12 mo PFI | 17 | 29.8 | 12 | 22.2 | 29 | |
| Platinum sensitive >12 mo PFI | 12 | 21.1 | 15 | 27.8 | 27 | |
PFI = platinum free interval